Recent Development in Metallic Nanoparticles for Breast Cancer Therapy and Diagnosis

Subhan, Abdus; Rahman, Mohammed M.

doi:10.1002/tcr.202100331

Cited by 18 publications

(7 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent decades, there has been a great improvement in OS of BRCA patients, but metastasis or death still occurs in 15% of patients ( Bertucci and Goncalves, 2017 ). Due to the high heterogeneity of BRCA, the effects of postoperative chemotherapy and endocrine therapy are significantly different ( Subhan and Muzibur Rahman, 2022 ). Although it is traditionally considered that the immunogenicity of BRCA is poor compared with melanoma ( Kalaora et al, 2022 ) and renal cell carcinoma ( Zhou et al, 2022 ), which have made enormous progress in immunotherapy, the latest studies suggest that immunotherapy may activate immune activation pathways and specifically kill tumor cells, providing a new way to further improve the prognosis of BRCA patients ( Adeshakin et al, 2022 ).…”

Section: Discussionmentioning

confidence: 99%

An Immune-Related Long Noncoding RNA Pair as a New Biomarker to Predict the Prognosis of Patients in Breast Cancer

et al. 2022

View full text Add to dashboard Cite

Background: Immune-related long non-coding RNAs (irlncRNAs) might remodel the tumor immune microenvironment by changing the inherent properties of tumor cells and the expression of immune genes, which have been used to predict the efficacy of immunotherapy and the prognosis of various tumors. However, the value of irlncRNAs in breast cancer (BRCA) remains unclear.Materials and Methods: Initially, transcriptome data and immune-related gene sets were downloaded from The Cancer Genome Atlas (TCGA) database. The irlncRNAs were extracted from the Immunology Database and Analysis Portal (ImmPort) database. Differently expressed irlncRNAs (DEirlncRNAs) were further identified by utilizing the limma R package. Then, univariate and multivariate Cox regression analyses were conducted to select the DEirlncRNAs associated with the prognosis of BRCA patients. In addition, the univariate and least absolute shrinkage and selection operator (LASSO) Cox regression analyses were performed to determine the DEirlncRNA pairs with the independent prediction capability of prognosis in BRCA patients. Finally, the chosen DEirlncRNA pair would be evaluated in terms of survival time, clinicopathological characteristics, tumor-infiltrating immune cells, immune checkpoints (ICs), signaling pathways, and potential small-molecule drugs.Results: A total of 21 DEirlncRNA pairs were extracted, and among them, lncRNA MIR4435-2HG and lncRNA U62317.1 were chosen to establish a risk signature that served as an independent prognostic biomarker in BRCA patients. Patients in the high-risk group had a worse prognosis than those in the low-risk group, and they also had an abundance of infiltration of CD4+ T and CD8+ T cells to enhance the immune response to tumor cells. Furthermore, the risk signature showed a strong correlation with ICs, signaling pathways, and potential small-molecule drugs.Conclusion: Our research revealed that the risk signature independent of specific DEirlncRNA pair expression was closely associated with the prognosis and tumor immune microenvironment in BRCA patients and had the potential to function as an independent prognostic biomarker and a predictor of immunotherapy for BRCA patients, which would provide new insights for BRCA accurate treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

An Immune-Related Long Noncoding RNA Pair as a New Biomarker to Predict the Prognosis of Patients in Breast Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Recent strides in the study of metallic nanoparticles (MNPs) have impacted the biomedicine landscape, attributable to their exceptional adaptability in diagnostics and therapeutic applications [ 304 ]. MNPs exhibit an array of distinguished properties: an enhanced electromagnetic field at their surface, a comprehensive suite of optical characteristics, efficient synthesis routes, facile manipulation of their surface chemistry, adaptability in surface modifications, low toxicity, biocompatibility, biofilm inhibition, reactive oxygen species formation, shape and morphology controllable, and easy functionalization.…”

Section: Nanoscale Drug Delivery Systemsmentioning

confidence: 99%

Breaking barriers: The potential of nanosystems in antituberculosis therapy

Carnero Canales,

Marquez Cazorla,

Marquez Cazorla

et al. 2024

Bioactive Materials

View full text Add to dashboard Cite

“…The use of these treatment methods has many side effects that reduce the quality of life of breast cancer sufferers 9 . Recently, researchers are looking for alternative therapy methods to control bacterial infections and cancers, and one of these approaches is the use of metallic nanoparticles 10 .…”

Section: Introductionmentioning

confidence: 99%

Niosomes-loaded selenium nanoparticles as a new approach for enhanced antibacterial, anti-biofilm, and anticancer activities

Haddadian

Robattorki

Dibah

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Targeted drug delivery and increasing the biological activity of drugs is one of the recent challenges of pharmaceutical researchers. Niosomes are one of the new targeted drug delivery systems that enhances the biological properties of drugs. In this study, for the first time, the green synthesis of selenium nanoparticles (SeNPs), and its loading into niosome was carried out to increase the anti-bacterial and anti-cancer activity of SeNPs. Different formulations of noisome-loaded SeNPs were prepared, and the physical and chemical characteristics of the prepared niosomes were investigated. The antibacterial and anti-biofilm effects of synthesized niosomes loaded SeNPs and free SeNPs against standard pathogenic bacterial strains were studied, and also its anticancer activity was investigated against breast cancer cell lines. The expression level of apoptotic genes in breast cancer cell lines treated with niosome-loaded SeNPs and free SeNPs was measured. Also, to evaluate the biocompatibility of the synthesized niosomes, their cytotoxicity effects against the human foreskin fibroblasts normal cell line (HFF) were studied using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay. The results illustrated that the optimal formulation had an average size of 177.9 nm, a spherical shape, and an encapsulation efficiency of 37.58%. Also, the results revealed that the release rate of SeNPs from niosome-loaded SeNPs and free SeNPs was 61.26% and 100%, respectively, in 72 h. Also, our findings demonstrated that the niosome-loaded SeNPs have significant antibacterial, anti-biofilm, and anticancer effects compared to the free SeNPs. In addition, niosome-loaded SeNPs can upregulate the expression level of Bax, cas3, and cas9 apoptosis genes while the expression of the Bcl2 gene is down-regulated in all studied cell lines, significantly. Also, the results of the MTT test indicated that the free niosome has no significant cytotoxic effects against the HFF cell line which represents the biocompatibility of the synthesized niosomes. In general, based on the results of this study, it can be concluded that niosomes-loaded SeNPs have significant anti-microbial, anti-biofilm, and anti-cancer effects, which can be used as a suitable drug delivery system.

show abstract

Recent Development in Metallic Nanoparticles for Breast Cancer Therapy and Diagnosis

Cited by 18 publications

References 150 publications

An Immune-Related Long Noncoding RNA Pair as a New Biomarker to Predict the Prognosis of Patients in Breast Cancer

An Immune-Related Long Noncoding RNA Pair as a New Biomarker to Predict the Prognosis of Patients in Breast Cancer

Breaking barriers: The potential of nanosystems in antituberculosis therapy

Niosomes-loaded selenium nanoparticles as a new approach for enhanced antibacterial, anti-biofilm, and anticancer activities

Contact Info

Product

Resources

About